Mucosta ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
53シェーグレン症候群3

53. シェーグレン症候群


臨床試験数 : 305 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT1031220298
27/08/202227/08/2022Mucosta trialA double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in dry eye with the Sjogren syndrome patients. - Mucosta trial Patients with dry eye complicated by Sjogren's syndromeEach study drug will be administered for a period of 12 weeks from the date of initiation of administration.

Mucosta group: Mucosta ophthalmic suspension is administered 4 times a day and observed at 0, 4 and 12 weeks.
Hyalein group: Hyalein ophthalmic suspension is administered 6 times a day and observed at 0, 4, and 12 weeks.
Shimizu DaisukeNULLRecruiting>= 18age oldNot applicableBoth40Phase 4Japan
2JPRN-UMIN000019009
2015/08/1914/09/2015The multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndromeThe multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndrome - The multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndrome The dry eye patients complicated with Sjogren's syndromeMucosta ophthalmic suspensionUD2%, q.i.d. and Soft Santear, t.d. for 4weeks in both eyes
Soft Santear, q.i.d. for 4weeks
Kyoto Prefectural University of MedicineNULLComplete: follow-up complete20years-oldNot applicableMale and Female60Not selectedJapan
3JPRN-UMIN000008427
2012/07/1313/07/2012Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome.Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. - Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. Patients with dry eye associated with Sjogren's syndrome.Mucosta ophthalmic suspension UD2%Kanazawa Medical UniversityNULLComplete: follow-up complete20years-oldNot applicableMale and Female30Not selectedJapan